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MECHANISMS OF DISEASE
Summary
Background Myocardial failure has a central role in the
complex pathophysiology of septic shock and contributes 
to organ failure and death. During the sepsis-induced
inflammatory process, specific factors are released that
depress myocardial contractile function. We aimed to identify
these mediators of myocardial depression in meningococcal
septic shock. 
Methods We combined gene-expression profiling with protein
and cellular methods to identify a serum factor causing
cardiac dysfunction in meningococcal septic shock. We
identified genes that were significantly upregulated in blood
after exposure to meningococci. We then selected for further
analysis those genes whose protein products had properties
of a myocardial depressant factor—specifically a 12–25 kDa
heat-stable protein that is released into serum shortly after
onset of meningococcal infection.
Findings We identified 174 significantly upregulated genes in
meningococcus-infected blood: six encoded proteins that were
of the predicted size and had characteristics of a myocardial
depressant factor. Of these, interleukin 6 caused significant
myocardial depression in vitro. Removal of interleukin 6 
from serum samples of patients with meningococcaemia and
from supernatants of inflammatory cells stimulated by
meningococci in vitro abolished the negative inotropic activity.
Furthermore, concentrations in serum of interleukin 6 strongly
predicted degree of myocardial dysfunction and severity of
disease in children with meningococcal septic shock.
Interpretation Interleukin 6 is a mediator of myocardial
depression in meningococcal disease. This cytokine and its
downstream mediators could be a target for future treatment
strategies.
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Introduction
Septic shock is a major cause of mortality and morbidity
in children and adults worldwide. Myocardial dysfunction
is a central component in the complex pathophysiology of
septic shock, and leads to impaired tissue perfusion,
multiorgan failure, and death. Improved treatment of
myocardial dysfunction in sepsis has been hampered by
poor understanding of the mechanisms involved. Presence
of NEGATIVELY INOTROPIC FACTORS released into plasma
during sepsis was first documented more than 30 years
ago,1 and has since been confirmed in many studies.2,3
However, the precise nature of a so-called MYOCARDIAL
DEPRESSANT FACTOR has not been established. 
Many investigators have attempted to characterise
myocardial depressant factors in plasma or serum of
patients with septic, haemorrhagic, or post-burn shock.2–6
Attempts to identify the nature of these factors have
produced differing data, including that the agent was of
low molecular weight2,4 or of a high molecular weight.3
Water-soluble2 and lipid soluble5 factors that act acutely2,3
or after prolonged incubation6 have been reported. 
A probable explanation for these conflicting data on the
identity of myocardial depressant factors is heterogeneity
of patients studied and diversity of their underlying
disorders. Many published series of patients with septic
shock included adults with a wide range of underlying
medical and surgical disorders whose sepsis was caused 
by many different gram-positive and gram-negative
organisms. Furthermore, because of an absence of precise
clinical markers of the time of onset of sepsis, patients
were studied at different timepoints in their illness. 
We postulated that myocardial depressant factors
released in gram-negative sepsis could be readily defined
by studying one clearly identified disease process affecting
previously healthy people without underlying medical or
surgical disorders. Meningococcal sepsis is the most
frequent infectious cause of death in children in the UK.
Myocardial failure is a major feature of meningococcal
sepsis.7 Severely affected patients have greatly impaired
cardiac function, unresponsive to conventional treatment,
which can lead to multiorgan hypoxia, ischaemia, and
failure.
We have previously reported that serum of children
with meningococcal septic shock contains a myocardial
depressant protein factor of 12–25 kDa,8 which is released
after exposure of peripheral blood cells to meningococci in
vitro, with maximum release happening at 3 h.8 We
therefore reasoned that this myocardial depressant activity
is attributable to a newly synthesised protein or proteins,
and that the gene or genes encoding this myocardial
depressant factor would be upregulated in peripheral
blood cells early after exposure to meningococci. We
postulated that the protein causing myocardial depression
could be identified with HIGH-DENSITY GENE MICROARRAY
EXPRESSION PROFILING, to predict candidate genes, based
on the known physiochemical properties of the protein. 
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We aimed to identify the myocardial depressant factor
or factors released from serum in meningococcal disease.
Methods
Patients
Between September, 1998, and July, 2002, we obtained
blood samples from patients with severe meningococcal
septic shock, for whom parental consent had been
obtained, on admission to the intensive care unit of 
St Mary’s Hospital, London, UK. We obtained approval
of the local research ethics committee of this institution.
Mean time of sampling was 5·4 h after initial presentation
to hospital and administration of antibiotics. We confirmed
the diagnosis of meningococcal disease clinically and
microbiologically by culture, serology, or rapid antigen
screen. Severity of disease was defined with the well-
validated PRISM (paediatric risk of mortality) III score,9 on
the basis of physiological variables measured in the first 
24 h of admission. 
Procedures
Characterisation of trace biologically active substances in
complex solutions such as serum or cell supernatants has
traditionally been undertaken by protein purification, which
needs large volumes of active solution. The small quantities
of serum available from critically-ill children with
meningococcal disease made this approach impractical. We
therefore combined high-density cDNA microarray
technology and conventional immunochemical methods. 
We obtained rat ventricular myocytes from adult male
Sprague-Dawley rats (300–400 g). Single-cell suspensions
were prepared by collagenase perfusion. We measured
myocyte contraction amplitude and speed of contraction
and relaxation before, during, and after exposure to 
the test substance, as previously described.8 Myocytes
were exposed to each of the candidate proteins
individually over a dose range similar to amounts seen in
meningococcal disease. 
We infected heparinised whole blood from two healthy
donors (adult volunteers) with 108 live meningococci,
serogroup B, type MC58, as previously described.8 Blood
was incubated at 37°C for 0, 1, 3, 6, 12, and 24 h. At every
timepoint we removed a sample and harvested the plasma
by centrifugation (1200 g, 10 min). We gathered the
remaining blood into RNA stabilisation fluid. Uninfected
control blood was obtained for every timepoint. 
We extracted total RNA with the PreAnalytix RNA
extraction kit (Qiagen, Crawley, UK), as described in 
the kit protocol. Duplicate RNA samples were obtained 
at every timepoint from each donor, with a resulting 
four RNA samples for each timepoint. After linear
amplification10 and reverse transcription to cDNA, 
we combined the RNA-derived cDNA sample with 
a reference cDNA (derived from a pool of RNA from a
panel of 11 human cell lines, of equal quantity). Every
sample was first labelled with two distinct fluorescent
nucleotides (Amersham Pharmacia, Chalfont, Bucks,
UK): Cy3-dUTP (550 nm) for the reference, 
and Cy5-dUTP (649 nm) for the sample. The probe 
was washed, concentrated, and competitively hybridised
to custom-printed cDNA microarrays containing 
37 632 hybridisation elements for about 18 000 expressed
human genes.11
We scanned the slides with laser microscopy (GenePix
4000A, Axon instruments, Union City, CA, USA), with
every spot on the array given a relative fluorescence ratio
for sample and reference RNA. Areas of the array with
blemishes or poor quality spots were flagged and excluded
from analysis. We filtered data so that only those spots
that were well measured on at least 80% of the arrays, and
showing at least two-fold change from baseline in both
donors, were included. The remaining gene expression
ratios were log-transformed and centred by subtracting
the median observed value on every array. Data were 
then zero-transformed—ie, baselined—with a custom
Microsoft Excel macro (DataProc).12 Specifically, the
average time zero measurement for each donor was then
subtracted from every subsequent timepoint measurement
to depict temporal response patterns of expression relative
to t=0 as the baseline. 
Transformed data were hierarchically clustered on the
gene axis with the average linkage method by Cluster
(version 2.20),13 and results were analysed with Treeview
software (version 1.60).13 All datasets and image files used
in the whole blood stimulation experiment are publicly
available in both raw and MIAME-compliant formats14
through the Stanford microarray database,15 and in the
webfigure (http://image.thelancet.com/extras/03art7298
webfigure.pdf). With the Stanford microarray database,15
data were selected from the microarrays for unique
arrayed cDNA elements that had a fluorescence intensity
in either channel of at least 2·5-fold over background
intensity for either the Cy3 or Cy5 channel. 
We isolated peripheral blood mononuclear cells from
donor blood by density gradient centrifugation, and
resuspended them in RPMI medium (Sigma Chemical,
Poole, UK) with 10% fetal calf serum, as previously
described.8 Cells were stimulated with 108 colony-
forming units per mL of heat-killed Neisseria meningitidis
for 4 h. After incubation, we recovered the supernatant 
by centrifugation (1200 g, 10 mins) and stored it at –80°C.
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Stimulate blood with meningococci
Recover RNA at 2–3 h
Identify genes upregulated by expression profile on high density
cDNA microarrays
Select candidate genes that are secreted,
molecular weight 12–25 kDa
Test candidates for biological activity
Figure 1: Strategy to identify myocardial depressant factors in
meningococcal septic shock
GLOSSARY
HIGH-DENSITY GENE MICROARRAY EXPRESSION PROFILING
A technique whereby the relative abundance or absence of thousands
of genes can be determined simultaneously. Fluorescence-labelled
RNA transcripts are hybridised onto a glass slide onto which specific
cDNA clones are spotted. The absolute fluorescence intensity of the
signal is then measured and a ratio of the genes present can be
calculated.
MYOCARDIAL DEPRESSANT FACTOR
Circulating factor or factors that impair cardiac contractility in septic
shock.
NEGATIVELY INOTROPIC FACTORS
Factors causing impaired cardiac contractility.
PLEIOTROPIC CYTOKINE
A cytokine that affects activity of various cell types.
Activated sepharose columns (HiTrap, Amersham
Biosciences, Bucks, UK) were coupled with 1 mg
polyclonal antihuman tumour necrosis factor  (TNF)
or with polyclonal antihuman interleukin 6 (R & D
Systems, Oxon, UK). We loaded supernatant of
peripheral blood mononuclear cells or meningococcal
serum onto the column. The unbound (cytokine-
depleted) fraction was eluted with Tyrode’s solution
(150·0 mmol/L NaCl, 5·4 mmol/L KCl, 1·2 mmol/L
MgCl2, 2·0 mmol/L CaCl2, 10 mmol/L Glu, and 5
mmol/L sodium HEPES with pH adjusted to 7·4, at
37°C). The bound (cytokine-containing) fraction was
recovered by eluting the column with glycine-HCl pH 3
solution and dialysing against water for 2 h and then
against Tyrode’s solution overnight with Visking tubing
(Visking, Liverpool, UK).
We measured concentrations in serum of interleukin 6
in patients’ samples and stimulated peripheral blood
mononuclear cells supernatant by ELISA with rabbit
polyclonal antihuman cytokines (Boehringer Mannheim,
Lewes, UK), as detailed in the kit protocol. 
To correlate interleukin 6 concentrations with disease
severity, we also included in our study patients from the
multicentre trial of rBPI21 in meningococcal sepsis.16
Samples were taken before administration of drug or
placebo, and access to data was granted by Xoma
(Berkeley, CA, USA).
Statistical analysis
We measured all outcomes on a continuous scale.
Differences in contraction amplitude and percentage
change in contraction amplitude between pairs of groups
were assessed with Mann-Whitney tests, whereas we used
the Kruskal-Wallis test to assess the difference in serum
concentration of interleukin 6 between different clinical
groups. We calculated the relation between serum
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Figure 2: Identification of genes coding for candidate myocardial depressant factors
Gene expression profiles of whole blood incubated with live meningococci for up to 24 h (infected) and control samples (uninfected). IL=interleukin.
IFNG=interferon . (A) 299 cDNAs (about 174 genes) were identified showing prominent responses to meningococcal infection and concordance in both
donors (as described in the webfigure). (B) Purple bars indicate genes that were upregulated at 3 h, were secreted, and had a molecular weight (MW) of
12–25 kDa. (C) Timecourse of expression of genes meeting all three myocardial depressant factor criteria.Depicted datapoints represent the geometric
mean of independent cDNA elements as a ratio (log2) relative to pretreatment timepoint. Error bars=SD.
concentration and PRISM III score with Pearson
correlation.
Role of the funding source
The sponsors of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report.
Results
Our experimental strategy to identify the myocardial
depressant factor or factors is summarised in figure 1.
We first sought to identify candidate genes that 
were upregulated on exposure of peripheral blood 
cells to meningococci. We identified a set of about 
174 genes with strongly altered expression after exposure
to meningococci, which were concordant in two separate
donors (figure 2 A; webfigure). Within this set of genes,
we found only six that fitted our criteria for myocardial
depressant factor candidates. 
The six myocardial depressant factor candidates
identified were interleukins 1, 1, and 6, IL-1RN
(interleukin 1 receptor antagonist), interferon , and TNF
(figure 2 C). Of these, IL-1RN was excluded from analysis
since we observed significant non-specific induction within
the uninfected time series of both donors. The remaining
five myocardial depressant factor candidates represent
major proinflammatory cytokines, and are canonical
markers of the sepsis-induced inflammatory process. 
We found close concordance between mRNA
expression and concentration of released protein for a
confirmatory subset of these genes with specific ELISA
for TNF, and interleukin 6 (figure 3), confirming the
validity of the gene expression profiling.
We tested recombinant human candidate proteins 
for myocardial depressant activity with isolated rat
cardiac myocytes. The effect of these proteins was
compared with myocardial depressant activity of serum
samples from patients with meningococcaemia and of
supernatants from inflammatory cells treated with
meningococci. Only interleukin 6 induced a dose-
dependent myocardial depression (figure 4 A). TNF
had no significant effect on myocyte contractility.
Addition of TNF to interleukin 6 did not increase the
myocardial depressant effect. At 20 000 pg/mL, TNF
caused a mean change in contraction amplitude of
2·8% (SD 5·1; n=5); at 100 000 pg/mL, the reduction
was –5·35% (SD 4·7). By contrast, 20 000 pg/mL of
interleukin 6 caused a mean change in contraction
amplitude of –13·9% (SD 3·3), whereas a combination
of TNF and interleukin 6 caused a mean change of
–17·6% (8·2; figure 4 A). 
We noted that purified recombinant interleukin 6 
also mimicked the chronic depressant effects of
meningococcal serum. Myocytes cultured with
interleukin 6 (1000 pg/mL) for 48 h had a mean
contraction amplitude of 4·97% (SD 2·9), whereas 
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Figure 3: Protein concentrations of TNF and interleukin 6
during in-vitro infection of whole blood with N meningitidis
Values are mean, error bars show SD. For corresponding mRNA
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contraction amplitude 
(A) Acute changes in contraction of cardiac myocytes following exposure
to TNF or interleukin 6. (B) Effect of TNF and interleukin 6 on myocyte
contraction after 48 h exposure.
that of cells exposed to a combination of TNF and
interleukin 6 was 3·48% (2·8; p=0·03, unpaired t test).
Myocytes cultured in cytokine-free conditions had 
a mean contraction amplitude of 6·77% (SD 3·2; n=36
for each condition). Thus, depressant activity of
interleukin 6 was similar in time course, duration, and
extent to that of meningococcal serum and
meningococcal activated peripheral blood mononuclear
cells supernatant (figure 4 B). TNF enhanced the
negative inotropic activity of interleukin 6 after
prolonged exposure, but had no significant depressant
activity alone or in combination with interleukin 6 on
acute exposure.
We compared the ability of serum from ten acutely ill
patients with meningococcal disease to induce
myocardial depression before and after removal of
interleukin 6 or TNF by immunoadsorption (figure 5).
Mean change in contraction amplitude of ten untreated
meningococcal serum samples was –16·74% (SD 4·5),
whereas in interleukin-6-depleted meningococcal 
serum, mean change was +4·08% (SD 3·2; n=10).
Immunoadsorption with an unrelated antibody
(antithrombomodulin) had no effect on the myocardial
depressant activity of meningococcal serum. Depletion
of interleukin 6 by affinity immunoadsorption
completely abolished the myocardial depressant 
activity of meningococcus-stimulated peripheral blood
mononuclear cells supernatants (figure 5). After
recovery of bound interleukin 6 from the sepharose
column, myocardial depressant activity was shown to be
present in the fraction adsorbed to the column. Removal
of TNF did not significantly reduce the negative
inotropic activity of meningococcal serum. Mean change
in contraction amplitude of myocytes exposed to
meningococcal serum before TNF removal was
–25·5% (SD 24·1; n=7), and that after TNF removal
MECHANISMS OF DISEASE
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M
ea
n 
ad
m
is
si
on
 in
te
rle
uk
in
 6
 
se
ru
m
 c
on
ce
nt
ra
tio
n 
(p
g/
m
L)
0
1·0103
1·0106
1·0109 r=0·58 (p<0·0001)
r2=0·34
0 4020 8060 100
PRISM III score
Ad
m
is
si
on
 in
te
rle
uk
in
 6
 c
on
ce
nt
ra
tio
n 
(p
g/
m
L)
0
Group 1
(n=9)
Group 2
(n=40)
Group 3
(n=38)
Group 4
(n=53)
100000
200000
300000
400000
A B
Figure 6: Association between interleukin 6 and clinical disease severity
(A) Correlation of PRISM III score and interleukin 6 serum concentration. (B) Severity of myocardial dysfunction on the basis of need for inotropic support.
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(p<0·0001, Kruskall-Wallis test).
was –10·5% (SD 9·1; p=0·13; n=7). Furthermore, the
fraction containing TNF did not have significant
myocardial depressant activity (mean change in
contraction amplitude –6·3% [SD 7·3; p=0·27; n=4]).
We analysed the association of serum concentration of
interleukin 6 with disease severity, as measured by the
PRISM III score, in 140 patients admitted with severe
meningococcal disease, and found a significant
correlation (r=0·58; p<0·0001; figure 6 A). Myocardial
dysfunction, as measured by need for inotropic agents,
was also correlated with interleukin 6 concentration:
amount of interleukin 6 in serum on admission was high
in patients with severe shock needing high-dose
inotropes (figure 6 B).
Discussion
We have shown that interleukin 6 has an important role
in myocardial depressant activity of meningococcal
serum. The time course of release of interleukin 6 
and its molecular weight accorded with the known
properties of the myocardial depressant factor or
factors.8 Recombinant interleukin 6 mimicked the
myocardial depressant effect of meningococcal serum on
rat cardiac myocytes, and removal of this cytokine 
from patients’ serum or meningococcal-stimulated
peripheral blood mononuclear cell supernatant
abolished activity. The close correlation of serum
concentrations of interleukin 6 on admission with
severity of cardiovascular failure in meningococcal
disease and of clinical disease severity lends support to
the clinical relevance of our findings. 
Interleukin 6 is a PLEIOTROPIC CYTOKINE that has been
characterised as a biomarker of early inflammatory
responses in sepsis. Findings of studies in a few patients
with meningococcal disease have established a relation
between interleukin 6 and disease severity,17–20 which
we have confirmed in our cohort of 140 patients.
Concentrations of interleukin 6 remain raised for some
24–48 h after disease presentation, which could account
for the persistent cardiac dysfunction seen during the
early days following the onset of septicaemia. 
Despite the well-documented release of interleukin 6
in sepsis, it has not generally been regarded as a central
mediator in the pathophysiology of septic shock, and
unlike TNF and interleukin 1, has not attracted
attention as a therapeutic target for trials of anti-
inflammatory agents in sepsis. Published work shows
that TNF and interleukin 1 are implicated in
myocardial dysfunction of sepsis.3 However, our results
in meningococcal disease do not preclude a role for
TNF and interleukin 1 in myocardial depression of
septic shock. We did not note any negative inotropic
effect of these cytokines. TNF might have some
synergistic activity on prolonged exposure. 
Gene microarray analysis of changes in RNA
expression on exposure of blood to meningococci adds 
a new dimension to our understanding of the
inflammatory process. In addition to known
inflammatory proteins, such as TNF and other
cytokines, hundreds of other genes are upregulated after
exposure of blood to meningococci, many of whose
functions are not known. However, although this
technology has provided an insight into the complexity
of the process, our findings show that it can also be used
to elucidate mechanisms if information from the
microarray can be linked to a carefully defined biological
question and combined with data from conventional
biochemical analysis. By relating data from the gene
expression profile of meningococcus-activated whole
blood to specific physical characteristics of the
myocardial depressant factor or factors, we were able to
rapidly identify candidate proteins to screen for
myocardial depressant activity in our established
bioassay.
Although we used only two donors for the gene array
strategy, the pattern of inflammatory response induced
by meningococci on exposure to whole blood has 
now been extensively documented.21–23 We have
previously shown that addition of 108 meningococci to
whole blood induces a highly consistent response, with
release into the plasma of cytokines such as TNF and
neutrophil products including elastase, and alteration in
expression of adhesion molecules, all happening within
3 h of exposure.21–23 Release of myocardial depressant
activity into the supernatant of meningococcus-activated
whole blood is also at a maximum at about 3 h.8 The
pattern of gene expression noted with the microarray
accords with previous data on the inflammatory
response studied at a protein level. 
Interleukin 6 has been shown to depress papillary
muscle contraction,24 and is negatively inotropic in
cultures of isolated chick and guineapig ventricular
myocytes.25,26 Our finding that the myocardial depressant
activity of serum from patients with meningococcaemia
is completely removed by affinity-adsorption of
interleukin 6, and that concentrations of this cytokine
correlate with cardiovascular morbidity, lend support to
the view that interleukin 6 is the principal mediator of
myocardial depression in meningococcal sepsis.
The mechanisms by which interleukin 6 exerts
negative inotropic activity are not well documented. Our
previous work suggested that the nitric oxide-cyclic
GMP pathway was not involved in the negative inotropic
activity of meningococcal serum.8 Furthermore,
interleukin 6 can bind directly to cells expressing the cell-
bound or soluble interleukin 6 receptor, which interacts
with the ubiquitous gp130 receptor. Changes in
expression of cellular or soluble receptors may affect
activity of this cytokine in sepsis. 
Interleukin 6 is upregulated in many infectious 
and inflammatory states, including cardiac surgery,
cardiogenic shock, and coronary bypass,27,28 and in gram-
negative and gram-positive sepsis. If this cytokine 
is indeed a major mediator of myocardial depression, as
our findings indicate, then treatment to block or
neutralise the myocardial depressant effects of
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RELEVANCE OF THIS PAPER TO PRACTICE
BACKGROUND
Septic shock is a complex catastrophic illness, which can progress
rapidly to death. Dissecting out all the parts of this illness is difficult,
especially because large samples are often not available from very sick
patients.
One distinct component of this illness in meningococcal sepsis is
myocardial dysfunction, which this paper focused on. By use of an 
in-vitro model of septic shock it was possible to select from large
numbers of genes six that were potentially implicated in the myocardial
dysfunction. Then, using samples from children with meningococcal
sepsis it was possible to show that removal of one of these proteins,
interleukin 6, abrogated ability of the samples to cause myocardial
depression—again in vitro. Finally, interleukin 6 was associated with
clinical outcome.
IMPLICATIONS
This paper links together gene expression analysis, physiology, and
prognosis to identify interleukin 6 as a plausible cause of myocardial
dysfunction in septic shock, which warrants further investigation as a
therapeutic target.
interleukin 6 could be a promising therapeutic direction,
not only in septic shock but also in other inflammatory
conditions associated with myocardial dysfunction. 
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